3Barone P, Poewe W, Albrecht S, et al. Pramipexole for the treatment of depressive symptoms in patients with Parkinson' s disease: a random- ised, double-blind, placebo-controlled trial. Lancet Neurol, 2010, 9 :573-580.
4Baker WL, Silver D, White CM, et al. Dopamine agonists in the treat- merit of early Parkinson' s disease : a meta-analysis. Parkinsenigm Relat Disont ,2009,15:287-294.
5Gao X, Chen H, Schwarzsehild MA, et al. Use of ibuprofen and risk of Parkinson disease. Neurology,2011,76 : 863 -869.
6Smeding HM, Speelman JD, Huizenga HM, et al. Predictors of cognitive and psychosoeial outcome after STN DBS in Parkinson' s Disease. J Neurol Neurosurg. Psychiatry, 2011,82:754-760.
7Trtister AI. Deep brain stimulation and neuropsyehology:a step forward? Nat Rev Neurol, 2011,7:480-481.
8Stone SS, Teixeira CM, Devito LM, et al. Stimulation of entorhinal cortex promotes adult neurogenesis and facilitates spatial memory. J Neurosei, 2011,31 : 13469-1384.
9Fuentes R, Petersson P, Siesser WB, et al. Spinal cord stimulation re- stores locomotion in animal models of Parkinson' s disease. Science, 2009,323:1578-1582.
10Caiazzo M, Dell' Anno MT, Dvoretskova E, et al. Direct generation of functional dopaminergic neurons from mouse and human fibroblasts. Na- ture, 2011,476:224-227.
7Gao X, Chen H. Use of ibuprofen and risk of Parkinson disease[J]. Neurology, 2011, 76: 863-869.
8Dawson T M, Dawson V L, Rare genetic mutations shed light on the pathogenesis of Parkinson disease[J], Clin Invest, 2003,111 ( 2 ) : 145-151.
9Barone P, Poewe W, Albrecht S, et al. Pramipexole for the treatment of depressive symptoms in patients with Parkinson' s disease: a randomized, double-blind, placebo-controled trial[J]. Lancet Neurol, 2010, ( 9 ) : 573-580.
10Smeding HM, Speerman JD, Huizenga HM, et al. Predictors of cognitive and psychosociar outcome after STN DBS in Parkinson' s Disease[J]. J Neurol Neurosurg. Psychiatry, 2011, 82: 754-760.
